Determinants of the reversal time of competitive neuromuscular block by anticholinesterases.
We have assessed, in 200 patients, the determinants of the reversal time of competitive neuromuscular block by anticholinesterase when alcuronium and atracurium neuromuscular block were antagonized by neostigmine 0.04 and 0.08 mg kg-1 and edrophonium 0.5 and 1.0 mg kg-1. A biexponential relationship was found between the reversal time (time from injection of anticholinesterase to a train-of-four ratio of 70%) and the degree of neuromuscular block at reversal (all groups; F ratio, P less than 0.05). Reversal time was determined by two processes: direct antagonism by the anticholinesterase and spontaneous recovery of the neuromuscular blocking agent, with the latter becoming the major determinant at profound levels of neuromuscular block (0-10% of control twitch height). Neostigmine, in the doses studied, appeared to have a higher "ceiling" of neuromuscular block which it completely antagonized, although edrophonium had a more rapid onset of action. The reversal time for alcuronium became progressively longer relative to atracurium as neuromuscular block increased because of the slower spontaneous recovery rate. Avoidance of profound neuromuscular block at the completion of surgery is required to ensure reliable antagonism of the block within 5-10 min by an anticholinesterase. Neostigmine 0.08 mg kg-1 was found to be the most effective agent in antagonizing profound neuromuscular block.
Beemer
G H
GH
Anaesthesia Department, Royal Melbourne Hospital, Victoria, Australia.
Bjorksten
A R
AR
Dawson
P J
PJ
Dawson
R J
RJ
Heenan
P J
PJ
Robertson
B A
BA
D000328:Adult; D000368:Aged; D000443:Alcuronium; D001279:Atracurium; D002800:Cholinesterase Inhibitors / Q000008:administration & dosage*; D004334:Drug Administration Schedule; D004491:Edrophonium / Q000494:pharmacology; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009388:Neostigmine / Q000494:pharmacology; D009407:Nerve Block / Q000379:methods*; D009466:Neuromuscular Blocking Agents / Q000037:antagonists & inhibitors*; D009469:Neuromuscular Junction / Q000187:drug effects; D013997:Time Factors
D002800:Cholinesterase Inhibitors; D009466:Neuromuscular Blocking Agents; D001279:Atracurium; D009388:Neostigmine; D004491:Edrophonium; D000443:Alcuronium